Indian multinational biotechnology company  Bharat Biotech on Friday said it has submitted all the data pertaining to its COVID-19 vaccine Covaxin to the WHO for Emergency Use Listing  and is awaiting feedback from the global health watchdog.

Sharing posts on its Twitter handle, Bharat Biotech noted: "COVAXIN clinical trial data was fully compiled & available in June 2021. All Data submitted for Emergency Use Listing (EUL) Application to World Health Organization in early July. We have responded to any clarifications sought by #WHO and are awaiting further feedback.”

As a reliable manufacturer with past approvals for its other vaccines, the company said it would not find it appropriate to speculate or comment on approval process and its timelines, it further said. "We are continuing to work diligently on obtaining WHO  Emergency ise Listing Procedure at the earliest, the vaccine maker added in multiple tweets.

In an update on its website, the WHO said it began rolling data of the vaccine on July 6.Rolling data allows the WHO to start its review right away, as information continues to come in, to accelerate the overall review process.

Union Health Minister Mansukh Mandaviya had also earlier met WHO Chief Scientist Dr Soumya Swaminathan and held discussions over the approval of Bharat Biotech's Covid-19 vaccine Covaxin.

Indian Railways launches Rail Kaushal Vikas Yojana

Kerala High Court denies anticipatory bail to fake female lawyer Cessy Xavier

President Ram Nath Kovind addresses special Himachal Pradesh Assembly session